Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
AssigneePiramal Enterprises Limited
InventorsSanjay Kumar, Rajiv Sharma, Vijaykumar Bhagwan Deore, Nilambari Nilkanth Yewalkar
Life of this patent
Estimating the term…
Abstract
The present invention relates to substituted phenyl alkanoic acid compounds designated as the compound of Formula (I) (as described herein) or a tautomer, a stereoisomer, a geometrical isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide, a S-oxide or a carboxylic acid isostere thereof; which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of compound of Formula (I) for the treatment of diseases or disorder mediated by GPR120.
Claims18
A compound of Formula (I)
- or a tautomer, a stereoisomer, a geometrical isomer, a pharmaceutically acceptable salt, a prodrug, an N-oxide, a S-oxide or a carboxylic acid isostere thereof;
- wherein:
- Ring A is 5- to 12-membered carbocycle, 5- to 12-membered heterocyclyl;
- (C6-C10)aryl, or 5- to 12-membered heteroaryl;
- provided that when q is 1 or 2, and W is a bond, then (C6-C10)aryl excludes naphthyl;
- Ring B is 5- to 12-membered carbocycle;
- Ring C is (C6-C10)aryl;
- W represents a bond, —(CR5R6)p—, —O—, —S— or —NR7—;
- X is —CR5R6—X1— or —X1—CR5R6—, wherein X1 is O, S or NR7
- Y is —(C(R4)2)q—;
- Q is —CO2M, —CONH2, —CONH[(C1-C6)alkyl], —CON[(C1-C6)alkyl]2, —CONHSO2(C1-C6)alkyl or a carboxylic acid isostere;
- M is hydrogen, deuterium or (C1-C6)alkyl;
- represents a single bond or a double bond;
- R1 at each occurrence is independently selected from the group consisting of hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkenyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, (C3-C10)cycloalkyl, heterocyclyl, (C6-C10)aryl, heteroaryl, (C6-C10)aryloxy, cyano, oxo, —NR7R8, —C(O)NR7R8, —C(S)NR7R8, —S(O)tR9 and —C(O)R10;
- R2 at each occurrence is independently selected from the group consisting of hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkenyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, (C3-C10)cycloalkyl, heterocyclyl, (C6-C10)aryl, heteroaryl, (C6-C10)aryloxy, cyano, oxo, —NR7R8, —C(O)NR7R8, —C(S)NR7R8, —S(O)tR9 and —C(O)R10;
- R3 at each occurrence is independently selected from the group consisting of hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, (C3-C10)cycloalkyl, heterocyclyl, (C6-C10)aryl, heteroaryl, cyano, −NR7R8, —S(O)tR9 and —C(O)R10;
- R4 at each occurrence is independently selected from the group consisting of hydrogen, (C1-C6)alkyl, halo(C1-C6)alkyl and halogen;
- or
- two R4 groups, together with the carbon atom to which they are attached can combine to form a (C3-C10)cycloalkyl or heterocyclyl;
- R5 and R6 are independently selected from the group consisting of hydrogen, deuterium, (C1-C6)alkyl, halo(C1-C6)alkyl and halogen;
- or
- R5 and R6 together with the carbon atom to which they are attached can combine to form
- i) 5- to 12-membered carbocycle or
- ii) 5- to 12-membered heterocyclyl containing 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S;
- R7 and R8 are independently selected from the group consisting of hydrogen, hydroxy, (C1-C6)alkyl, (C1-C6)alkenyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10)cycloalkyl, heterocyclyl, (C6-C10)aryl, heteroaryl, (C6-C10)aryloxy, —S(O)tR9;
- or
- R7 and R8, together with the nitrogen atom to which they are attached combine to form heterocyclyl;
- R9 and R10 are independently selected from the group consisting of hydrogen, hydroxy, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10)cycloalkyl, heterocyclyl, (C6-C10)aryl, heteroaryl and —NR7R8;
- m is 0, 1, 2 or 3;
- n is 0, 1, 2 or 3;
- o is 0, 1 or 2;
- p is 1 or 2;
- q is 1, 2, 3 or 4;
- t is 0, 1 or 2;
- wherein:
- (C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkenyl, halogen, halo(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C3-C10)cycloalkyl, (C6-C10)aryl, (C6-C10)aryloxy, heterocyclyl, heteroaryl, amino, cyano, nitro, —NH(C1-C6)alkyl, —N[(C1-C6)alkyl]2, —C(O)(C1-C6)alkyl, —C(O)O(C1-C6)alkyl, —C(O)NH2, —C(O)NH(C1-C6)alkyl, —C(O)N[(C1-C6)alkyl]2 and —C(O)NHSO2(C1-C6)alkyl;
- (C3-C10)cycloalkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkenyl, halogen, halo(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, halo(C1-C6)alkoxy, amino, cyano and nitro;
- carbocycle is a 5- to 12-membered ring which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkenyl, halo(C1-C6)alkyl, hydroxy, halogen, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C6-C10)aryl, (C3-C10)cycloalkyl, heteroaryl, heterocyclyl, amino, cyano, nitro, —C(O)O(C1-C6)alkyl, —C(O)NR7R8 and —S(O)tR9;
- wherein R7, R8, R9 and t are as defined above;
- heterocyclyl is a 5- to 12-membered ring which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkenyl, halogen, halo(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocyclyl, heteroaryl, amino, cyano, nitro, oxo, —NR7R8, —C(O)NR7R8, —S(O)tR9 and —C(O)R10;
- wherein R7, R8, R9, R10 and t are as defined above;
- (C6-C10)aryl is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkenyl, halogen, halo(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocyclyl, heteroaryl, amino, cyano, nitro, —C(O)O(C1-C6)alkyl, —C(O)NR7R8 and —S(O)tR9;
- wherein R7, R8, R9 and t are as defined above;
- heteroaryl is a 5- to 12-membered ring which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkenyl, halogen, halo(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocyclyl, heteroaryl, amino, cyano, nitro, —C(O)NR7R8 and —S(O)tR9;
- wherein R7, R8, R9 and t are as defined above.
A compound selected from the group consisting of:
- 4-(4-((4′-(1-cyanocyclopropyl)-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl) butanoic acid;
- 4-(4-((2-(5,6,7,8-tetrahydroquinolin-3-yl)cyclohex-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(2,3-dihydro-1H-inden-5-yl)cyclohex-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)cyclohex-1-en-1-yl)methoxy)phenyl) butanoic acid;
- 4-(4-((4′-cyano-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((4′-methoxy-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((4′-cyclopropyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(6-amino-5-(trifluoromethyl)pyridin-3-yl)cyclohex-1-en-1-yl)methoxy)phenyl) butanoic acid;
- 4-(4-((2-(5,6,7,8-tetrahydronaphthalen-2-yl)cyclohex-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-([1,1′-bi(cyclohexane)]-1,1′-dien-2-ylmethoxy)phenyl)butanoic acid;
- 4-(4-((3′-methyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2′-methyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(6-methoxypyridin-3-yl)cyclohex-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((4′-methyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(p-tolyl)cyclooct-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(m-tolyl)cyclooct-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(o-tolyl)cyclooct-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-phenylcyclooct-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(4-cyclopropylphenyl)cyclooct-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(4-(1-cyanocyclopropyl)phenyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(p-tolyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(4-cyclopropylphenyl)cyclododec-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(o-tolyl)cyclopent-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-phenylcyclopent-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(4-cyclopropylphenyl)cyclopent-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(4-cyclopropylphenyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(m-tolyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(o-tolyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-phenylcyclododec-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(p-tolyl)cyclododec-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(2,3-dihydrobenzofuran-5-yl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(2,3-dihydrobenzofuran-5-yl)cyclohex-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(2,3-dihydrobenzofuran-5-yl)cyclopent-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(p-tolyl)cyclopent-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(m-tolyl)cyclopent-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(5-methylthiophen-2-yl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(pyridin-3-yl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(4-methoxyphenyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(6-methoxypyridin-3-yl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(bicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)cyclohept-1-en-1-yl)methoxy)phenyl) butanoic acid;
- 4-(4-((2-(2-methylbenzo[d]thiazol-5-yl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(p-tolyloxy)cyclohex-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-cyclohex-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(p-tolyloxy)cyclohept-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((4′-(1-cyanocyclopropyl)-4-methyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy) phenyl)butanoic acid;
- 4-(4-((4-fluoro-4′-methyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methoxy)phenyl)butanoic acid;
- 4-(4-((2-(p-tolyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoate metformin salt;
- 4-(4-((2-(p-tolyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoate, piperazine-1,4-diium salt;
- 4-(4-((2-(p-tolyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoate,2-hydroxyethanaminium salt;
- 4-(4-((2-(p-tolyl)cyclohept-1-en-1-yl)methoxy)phenyl)butanoate, sodium salt;
- 4-(4-((2-phenoxycyclohex-1-en-1-yl)methoxy)phenyl)butanoic acid;
- 3-(4-((2-(5,6,7,8-tetrahydronaphthalen-2-yl)cyclohept-1-en-1-yl)methoxy) phenyl)propanoic acid;
- 3-(4-((2-(p-tolyl)cyclohept-1-en-1-yl)methoxy)phenyl)propanoic acid;
- 3-(4-((2-(4-cyclopropylphenyl)cyclohept-1-en-1-yl)methoxy)phenyl)propanoic acid;
- and
- 3-(4-((2-(4-(1-cyanocyclopropyl)phenyl)cyclohept-1-en-1-yl)methoxy)phenyl) propanoic acid;
- or a stereoisomer, a tautomer, a geometrical isomer, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.